|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00407121 |
|
Date of registration:
|
01/12/2006 |
|
Primary sponsor: |
|
|
Public title:
|
Intravitreal Bevacizumab for Inflammatory Neovascular Membranes
|
|
Scientific title:
|
Intravitreal Bevacizumab for the Treatment of Neovascular Membranes in Patients With Intraocular Inflammation |
|
Date of first enrolment:
|
August 2006 |
|
Target sample size:
|
|
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00407121 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
|
|
|
Countries of recruitment
|
|
Mexico
| | | | | | | |
|
Contacts
|
|
Name:
|
LuzElena Concha-Del Rio, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Asociacion para Evitar la Ceguera en Mexico |
|
|
Name:
|
Veronica Kon-Jara, MD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Asociacion para Evitar la Ceguera en Mexico |
| |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Clinical Diagnose
- Patient Consent
- Chronic stage of inflammation
Exclusion Criteria:
- only eye
- age lower than 30 yo.
- Systemic condition
Age minimum:
25 Years
Age maximum:
60 Years
Gender:
Both
|
|
Health Condition(s) or Problem(s) studied
|
|
Multifocal Choroiditis
|
|
Serpiginous Choroiditis
|
|
Vogt Koyanagi Harada Disease
|
|
Intervention(s)
|
|
Drug: Bevacizumab
|
|
Procedure: Intravitreal Injection of Bevacizumab
|
|
Primary Outcome(s)
|
|
Best corrected visual acuity
|
|
Leakage in Fluorescein angiogram
|
|
Retinal thickness by OCT
|
|
Secondary ID(s)
|
|
APEC-0025
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|